Abliva AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABLI.ST research report →
Companyabliva.com
Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments.
- CEO
- Ellen K. Donnelly
- IPO
- 2008
- Employees
- 6
- HQ
- Lund, SE
Price Chart
Valuation
- Market Cap
- $715.67M
- P/E
- -4.91
- P/S
- 5223.90
- P/B
- 7.60
- EV/EBITDA
- -7.30
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -50132.85%
- Op Margin
- -70472.99%
- Net Margin
- -69714.60%
- ROE
- -144.27%
- ROIC
- -156.50%
Growth & Income
- Revenue
- $137.00K · 0.00%
- Net Income
- $-95,509,000 · 0.00%
- EPS
- $-0.09 · 0.00%
- Op Income
- $-96,548,000
- FCF YoY
- -1044.16%
Performance & Tape
- 52W High
- $0.46
- 52W Low
- $0.11
- 50D MA
- $0.44
- 200D MA
- $0.26
- Beta
- 0.75
- Avg Volume
- 3.87M
Get TickerSpark's AI analysis on ABLI.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ABLI.ST Coverage
We haven't published any research on ABLI.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ABLI.ST Report →